Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP820S011
- Development stage
- Preclinical
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Gene Therapies
- Administration
- Ophthalmic
01
Overview
DWP820S011 is an experimental gene therapy candidate currently in preclinical development by Daewoong Pharmaceutical for the treatment of retinitis pigmentosa (RP). Retinitis pigmentosa is a group of rare genetic disorders characterized by the progressive degeneration of photoreceptor cells in the retina, leading to severe vision loss and potential blindness. DWP820S011 is designed to address the underlying pathology of the disease by delivering therapeutic genetic material to the retinal cells, typically utilizing a viral vector such as an adeno-associated virus (AAV). The program aims to provide a mutation-independent or targeted approach to preserve retinal function and prevent further cell death in patients suffering from this debilitating condition.
Beyond the preview
Go deeper on DWP820S011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP820S011.